Immune Checkpoint B7x (B7-H4/B7S1/VTCN1) is Over Expressed in Spontaneous Canine Bladder Cancer: The First Report and its Implications in a Preclinical Model.
Journal Information
Full Title: Bladder Cancer
Abbreviation: Bladder Cancer
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Urology & Nephrology
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"CONFLICT OF INTEREST X. Zang is an inventor on patent number US 9447186 B2, which covers the topic of cancer immunotherapy targeting B7x. The remaining authors declare no competing financial interests."
"FUNDING D. Chand is supported by the Thanks to Scandinavia/Borge endowment. This work was supported by NIH R01CA175495 and R01DK100525 (X. Zang)."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025